135 related articles for article (PubMed ID: 38583157)
1. Protocol to identify flavonoid antagonists of the SARS-CoV-2 main protease.
Yang M; Lin L; Flaumenhaft R
STAR Protoc; 2024 Jun; 5(2):102990. PubMed ID: 38583157
[TBL] [Abstract][Full Text] [Related]
2. Fluorogenic
Ihssen J; Faccio G; Yao C; Sirec T; Spitz U
STAR Protoc; 2021 Sep; 2(3):100793. PubMed ID: 34423318
[TBL] [Abstract][Full Text] [Related]
3. Natural Polyphenols Inhibit the Dimerization of the SARS-CoV-2 Main Protease: The Case of Fortunellin and Its Structural Analogs.
Panagiotopoulos AA; Karakasiliotis I; Kotzampasi DM; Dimitriou M; Sourvinos G; Kampa M; Pirintsos S; Castanas E; Daskalakis V
Molecules; 2021 Oct; 26(19):. PubMed ID: 34641612
[TBL] [Abstract][Full Text] [Related]
4. Invalidation of geraniin as a potential inhibitor against SARS-CoV-2 main protease.
Zhang R; Yan H; Zhou J; Liu X; Chen Y
Nat Prod Res; 2024 Jun; 38(12):2078-2081. PubMed ID: 37533400
[TBL] [Abstract][Full Text] [Related]
5. Identification of potential plant-based inhibitor against viral proteases of SARS-CoV-2 through molecular docking, MM-PBSA binding energy calculations and molecular dynamics simulation.
Gogoi B; Chowdhury P; Goswami N; Gogoi N; Naiya T; Chetia P; Mahanta S; Chetia D; Tanti B; Borah P; Handique PJ
Mol Divers; 2021 Aug; 25(3):1963-1977. PubMed ID: 33856591
[TBL] [Abstract][Full Text] [Related]
6. Conserved interactions required for inhibition of the main protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Shitrit A; Zaidman D; Kalid O; Bloch I; Doron D; Yarnizky T; Buch I; Segev I; Ben-Zeev E; Segev E; Kobiler O
Sci Rep; 2020 Nov; 10(1):20808. PubMed ID: 33257760
[TBL] [Abstract][Full Text] [Related]
7. Advances Toward COVID-19 Therapies Special Issue.
Neamati N
J Med Chem; 2022 Feb; 65(4):2713-2715. PubMed ID: 35138859
[No Abstract] [Full Text] [Related]
8. Chrysin 7-O-β-D-glucuronide is not a potential inhibitor against SARS-CoV-2 main protease.
Zhang R; Zhou J; Yan H; Liu X; Chen Y
Int J Antimicrob Agents; 2024 May; 63(5):107136. PubMed ID: 38460738
[No Abstract] [Full Text] [Related]
9. Glycyrrhizic acid conjugates with amino acid methyl esters target the main protease, exhibiting antiviral activity against wild-type and nirmatrelvir-resistant SARS-CoV-2 variants.
Le UNP; Chang YJ; Lu CH; Chen Y; Su WC; Chao ST; Baltina LA; Petrova SF; Li SR; Hung MC; Lai MMC; Baltina LA; Lin CW
Antiviral Res; 2024 Jul; 227():105920. PubMed ID: 38821317
[TBL] [Abstract][Full Text] [Related]
10. Epigallocatechin-3-gallate, an active ingredient of Traditional Chinese Medicines, inhibits the 3CLpro activity of SARS-CoV-2.
Du A; Zheng R; Disoma C; Li S; Chen Z; Li S; Liu P; Zhou Y; Shen Y; Liu S; Zhang Y; Dong Z; Yang Q; Alsaadawe M; Razzaq A; Peng Y; Chen X; Hu L; Peng J; Zhang Q; Jiang T; Mo L; Li S; Xia Z
Int J Biol Macromol; 2021 Apr; 176():1-12. PubMed ID: 33548314
[TBL] [Abstract][Full Text] [Related]
11. Structure-based screening of novel lichen compounds against SARS Coronavirus main protease (Mpro) as potentials inhibitors of COVID-19.
Joshi T; Sharma P; Joshi T; Pundir H; Mathpal S; Chandra S
Mol Divers; 2021 Aug; 25(3):1665-1677. PubMed ID: 32602074
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 M
Citarella A; Scala A; Piperno A; Micale N
Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33921886
[TBL] [Abstract][Full Text] [Related]
13. Protocol for high-throughput screening of SARS-CoV-2 main protease inhibitors using a robust fluorescence polarization assay.
Zhang J; Yan H; Yan G; Liu X; Wang Y; Chen Y
STAR Protoc; 2022 Dec; 3(4):101794. PubMed ID: 36317181
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive virtual screening of 4.8 k flavonoids reveals novel insights into allosteric inhibition of SARS-CoV-2 M
Jiménez-Avalos G; Vargas-Ruiz AP; Delgado-Pease NE; Olivos-Ramirez GE; Sheen P; Fernández-Díaz M; Quiliano M; Zimic M;
Sci Rep; 2021 Jul; 11(1):15452. PubMed ID: 34326429
[TBL] [Abstract][Full Text] [Related]
15. Machine learning combines atomistic simulations to predict SARS-CoV-2 Mpro inhibitors from natural compounds.
Nguyen TH; Thai QM; Pham MQ; Minh PTH; Phung HTT
Mol Divers; 2024 Apr; 28(2):553-561. PubMed ID: 36823394
[TBL] [Abstract][Full Text] [Related]
16. Targeting the Main Protease of SARS-CoV-2: From the Establishment of High Throughput Screening to the Design of Tailored Inhibitors.
Breidenbach J; Lemke C; Pillaiyar T; Schäkel L; Al Hamwi G; Diett M; Gedschold R; Geiger N; Lopez V; Mirza S; Namasivayam V; Schiedel AC; Sylvester K; Thimm D; Vielmuth C; Phuong Vu L; Zyulina M; Bodem J; Gütschow M; Müller CE
Angew Chem Int Ed Engl; 2021 Apr; 60(18):10423-10429. PubMed ID: 33655614
[TBL] [Abstract][Full Text] [Related]
17. Development of a Biosafety Level 1 Cellular Assay for Identifying Small-Molecule Antivirals Targeting the Main Protease of SARS-CoV-2: Evaluation of Cellular Activity of GC376, Boceprevir, Carmofur, Ebselen, and Selenoneine.
Fukumoto Y; Suzuki N; Hara R; Tanaka YK; Ogra Y
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891954
[TBL] [Abstract][Full Text] [Related]
18. In silico screening of potential inhibitors from Cordyceps species against SARS-CoV-2 main protease.
Deshmukh N; Talkal R; Lakshmi B
J Biomol Struct Dyn; 2024 Jun; 42(9):4395-4411. PubMed ID: 37325819
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 Main Protease Active Site Ligands in the Human Metabolome.
Sardanelli AM; Isgrò C; Palese LL
Molecules; 2021 Mar; 26(5):. PubMed ID: 33807773
[TBL] [Abstract][Full Text] [Related]
20. An Updated Review on SARS-CoV-2 Main Proteinase (M
Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
